Tempus AI

Tempus AI Debt Growth

The Year-over-Year Debt Growth of Tempus AI (TEM) as of Nov 2, 2026 is 184.66 %. In the previous year, Year-over-Year Debt Growth was -3.16 % — a change of -5,935.56% (higher).

Debt Growth

184.66 %

YoY

-5,935.56%

Last updated:

Year-over-Year Debt Growth of Tempus AI is 2025 184.66 % . Year-over-Year Debt Growth of Tempus AI was 2024 -3.16 % . It decreases by -5,935.56% higher compared to the previous year.

The Tempus AI Debt Growth history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Debt Growth
Date
Debt Growth
Jan 1, 2020
9,600.89 USD
Jan 1, 2021
-4.97 USD
Jan 1, 2022
63.15 USD
Jan 1, 2023
15.35 USD
Jan 1, 2024
-3.16 USD
Jan 1, 2025
184.66 USD
The Tempus AI Debt Growth history
YEARDebt GrowthYoY
184.66 %-5,935.56%
-3.16 %-120.62%
15.35 %-75.70%
63.15 %-1,370.15%
-4.97 %-100.05%
9,600.89 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Tempus AI Stock analysis

What does Tempus AI do? Tempus AI Inc provides next generation diagnostics through genomics, data, and AI applications. Its genomics product line includes next generation sequencing, diagnostics, PCR, profiling, molecular genotyping, and pathology testing. The AI applications focus on algorithmic diagnostics, software as a medical device, and clinical decision support tools. The primary AI product Next uses machine learning to identify care gaps for oncology and cardiology patients. The company serves healthcare providers and life sciences organizations seeking personalized medicine solutions. Tempus AI Inc's revenue comes from its genomics and AI product lines. The genomics services are delivered through its laboratories, offering sequencing, diagnostics, and molecular testing. The AI applications, particularly Next, are sold as software solutions to healthcare institutions. The target customers are healthcare providers and life sciences companies that require advanced diagnostic tools for personalized treatment plans. The company operates in the Life Sciences Tools & Services industry, focusing on oncology and cardiology segments. The company's genomics product line generates revenue through laboratory services for molecular pathology testing. AI applications like Next are sold as medical device software, targeting healthcare institutions for clinical decision support. The primary segments served are oncology and cardiology, where personalized medicine is critical. The company's products are designed to integrate with existing healthcare data systems to improve patient care outcomes. Tempus AI is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Tempus AI stock

Year-over-Year Debt Growth of Tempus AI is 184.66 % in 2025.

On Eulerpool you can find the complete historical development of Year-over-Year Debt Growth Tempus AI since 2006 – with annual values, charts, and detailed analysis.

Debt growth measures the percentage change in total debt. Rising debt growth should be compared with revenue and earnings growth to assess sustainability.

To evaluate Year-over-Year Debt Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year Debt Growth.

Year-over-Year Debt Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year Debt Growth's Tempus AI historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — Tempus AI

All Key Metrics — Tempus AI